Pancreatic Cancer Research

Clinical trialEarly Phase 1Active not recruiting

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

18F-FAC PET Imaging to Quantify Gemcitabine Tumor Drug Uptake and Biodistribution in Pancreatic Cancer Patients

Outcome
Ongoing
Phase
Early Phase 1
Status
Active not recruiting
Study type
Interventional
Start
18 November 2021
Listed end
18 November 2026
Enrollment
30 participants
Sites
1
Primary outcomes
Tumor drug uptake within PDAC tumors prior at pre-treatment baseline
Sponsor type
Academic / other
Results posted
No
Last update
3 September 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to find out whether a pre-treatment PET scan using the experimental imaging tracer 18F-FAC can show how much of the standard chemotherapy for PDAC may be taken up by the cancer.